Ultrabiotic

Resilient, Well-Research Bacteria Strains

When you are given antibiotics for a sore throats or other infections, the antibiotic ends up wiping out their normal, healthy bacterial lining that plays a significant role in their health. Without this essential bacteria present in their gut, you are prone to chronic infections, nutrient deficiencies and faulty digestion. It can take up to six months to rebuild the bacterial lining after just one round of antibiotics It is essential to supplement with probiotics after any course of antibiotics.

Mainstream probiotic marketing focuses solely on the number of bacteria in the capsule while Aceva focuses on the quality of the bacteria, the age of the bacteria, the research on the individual strains and the process of freeze drying the bacteria to ensure viability. Ultrabiotic strains were researched in 23 studies proving clinical efficacy in numerous health related conditions.

The Ultrabiotic Difference:

• Formulated with a fifty percent more bacteria than the label claim for maximum potency

• Researched strains are verified as authentic using taxonomic analysis

• All strains grown in a GMO-free medium and harvested during the growth phase to ensure the bacteria are active and resilient

• Proprietary lyoprotective agents are used to protect bacteria during freeze drying

Ultrabiotic Benefits:

• Restoration of Intestinal Microflora*

• Growth Inhibition of Pathogenic Bacteria*

• Strong Resistance to Chemotherapy Agents*

• Enhance Immune System by Producing IFNs, TNF, NK Cells, IL-1, IL-2, and IL-6 Protecting Against Infections and Cancer Cells*

• Strains Produce Essential Amino Acids and Vitamins*

• Strong Resistance to Antibiotics*

• Highly Active Against Salmonella, Escherichia, Staphylococcus and Food Spoilage Microorganisms*

• Anti-allergy and Anti-inflammatory Function*

• Reduces Symptoms of Colitis Complicated by Dysbiosis*

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

WARNING:  Consuming this product can expose you to chemicals including lead, which is known to the State of California to cause birth defects or other reproductive harm.  For more information go to www.P65Warnings.ca.gov/food.

Suggested Use:

As a dietary supplement, take one (1) capsule one time per day or as directed by your healthcare professional.

Caution:

As with any dietary supplement, consult your healthcare practitioner before using this product, especially if you are pregnant, nursing, anticipate surgery, take any medication or are otherwise under medical supervision.

Formulated To Be Free of Allergens Derived From:

Wheat, soy, eggs, fish, crustacean shellfish, tree nuts, peanuts, artificial preservatives, sweeteners, color and flavors.

* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

References and Research Abstracts Supporting Ultrabiotic

1. D. Zabolotny, L. Shynkarenko, O. Melnikov, L. Volosevich, І. Zarytska, О. Goloborodko, G. Karpenko, О. Bolyska, D. Zabolotna. Application of the probiotic medication “Acidolor” (L.rhamnosus LB3) in patients with chronic tonsillitis and evaluation of its efficacy; Journal of ear, nose and throat diseases, No5, 2003, page.2-9

2. D. Zabolotny, L. Volosevich, І. Zarytskа, V.D. Zabolotna. Perspectives of biotherapy in ENT diseases; Journal of ear, nose and throat diseases, No3-с, 2003, p.180-181

3. O. Volska, D. Zabolotna. Study of the mechanisms of antagonistic activity of the Probiotics drugs. Journal of ear, nose and throat diseases, No3-с, 2003, p.164-165

4. L. Shynkarenko, N. Dehtyrenko. Research of the Chemotherapy drugs influence on Lactic Acid Bacteria cells. Scientific news of the NTU “KPI”, 2004, 1 (33), pp.135-140

5. Shynkarenko L., Dehtyrenko N. Adhesion potency of lactic acid bacteria as factor for selection of Probiotic strains. Scientific news of the NTU “KPI”, 2004, 3 (35), pp.102-106

6. Zabolotny D., Melnilkov О., Zabolotnaya D., Shynkarenko L. Probiotic modulation of the immunogenesis in the experiment. Immunology and allergy, 1, 2006., p.19-21

7. О. Melnikov, D. Zabolotnaya. Experimental investigation of the Probiotic influence on the palate tonsils cells in patients with chronic tonsillitis in vitro. The journal of ear, nose and throat diseases, 2006, 3, pp.24-27.

8. Volska, L. Shynkarenko, I. Zarytska, D. Zabolotna. Study of the possibility of the using of the Lactobacilli for treatment and prevention of the Candida infections in ENT-organs. Odessa medical Journal, 2006, 4 (96), pp.32-36

9. О. Melnikov, D. Zabolotnaya, L. Kalinovskaya, V. Simonenko. Investigation of the functional and morphochemical characteristics of the cells and tissues under the conditions of the co-cultivation with L.rhamnosus LB3. The journal of ear, nose and throat diseases, 4, 2007, 170-172.

10. Timoshok N, Shynkarenko L, Starovoytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L.delbrueckii 86, L.rhamnosus LB3 to compare with Del-Immune V and Lactobacterin (L.plantarum); 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p.264

11. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Immunomodulating abilities of Lactic Acid Bacteria.2009; Microbiol.J.,V71, 3, pp.41-47

12. Report on clinical use of the probiotic cells Lactobacillus delbrueckii LE and their lysate. A.S Prylutskyy, MD, PhD, Clinical Immunology and Allergy Department, Donetsk State Medical University, 1999

13. Savtova Z.D., Shpylevaya S.I., Tarutinov V.I., Rogatskaya V.P., NMeniok T.A., Nikolsky I.S., Mosienko V.S., Shynkarenko L.M., Chekhun V.F. Immune correction by an Immunomodulator from lactobacillus delbrueckii LE in a combined therapy of breast cancer at stages II and IV. Oncology 2000; 22:211-214

14. Shpylevaya S.I., Tarutinov V.I., Mosienko V.S., Rogatskaya V.P., Ponomarev I.O., Shynkarenko L.M., Chekhun V.F. Correction of leucopenia by a new probiotic immunomodulator Lactobacillus delbrueckii product in combined treatment of breast cancer. Oncology, 2000; 2 (1-2):83-86

15. D. Zabolotny, L. Shynkarenko, О. Melnikov, L. Volosevich, І. Zarytska, О. Goloborodko, G. Karpenko, О. Bolyska, D. Zabolotna. Application of the probiotic medication “Acidolor” in patients with chronic tonsillitis and evaluation of its efficacy; Journal of ear, nose and throat diseases, No5, 2003, page.2-9

16. L. Shynkarenko, N. Dehtyrenko. Research of the Chemotherapy drugs influence on Lactic Acid Bacteria cells. Scientific news of the NTU “KPI”, 2004, 1 (33), pp.135-140

17. Volska, L. Shynkarenko, I. Zarytska, D. Zabolotna. Study of the possibility of the using of the Lactobacilli for treatment and prevention of the Candida infections in ENT-organs. Odessa medical Journal, 2006, 4 (96), pp.32-3

18. Starovoytova S., Gorchakov V. Lactic Acid Bacteria strain Selection for Effective Probiotics Compositions. 2006, Scientific News of NTU “KPI”, v5, pp.100-103

19. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Interferon induction activity of Lactic Acid Bacteria; 2007, Immunology and Allergy (Ukrainian), #4, pp. 24-27

20. Starovoytova S., Oryabinska L, Gorchakov V. Cholinesterase and protease activity of Lactic Acid Bacteria in vitro ; 2007, Environment and Health, #4 (43), pp.68-71

21. Starovoytova S, Timoshok N, Spivak N. Influence of Lactic Acid bacteria associated cultures at mice experimental meningoencephalytic herpes infection; 2008, In Abstracts of International Conference “Antibacterial and anti-viral therapy on hospital treatment”, Charkov, Ukraine, pp.316-317

22. Timoshok N, Shynkarenko L, Starovoytova S, Spivak N. Investigation of interferon induction activity of new Probiotic composition and strains L.delbrueckii 86, L.rhamnosus to compare with Del-Immune V and Lactobacterin (L.plantarum); 2009, IIX Congress of Ukrainian Microbiological Society, Abstracts Book, p.264

23. Starovoytova S, Timoshok N, Gorchakov V, Spivak N. Immunomodulating abilities of Lactic Acid Bacteria.2009; Microbiol.J., V71, #3, pp.41-47